Oncologic outcomes after radical surgery for periampullary cancer in octogenarians

Sung Hyun Kim¹, Jae Uk Chong¹, Jin Hong Lim¹, Moon Jae Chung², Jeong Youp Park², Seung Min Bang², Seung Woo Park², Ho Kyung Hwang¹, Chang Moo Kang¹, Woo Jung Lee¹, and Kyung Sik Kim¹

Departments of ¹Hepatobiliary and Pancreatic Surgery and ²Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Backgrounds/Aims: Interest in treatments for elderly patients has increased with life expectancy, and various studies have reported on the safety and feasibility of radical surgery in elderly patients with cancer. Here, we investigated oncologic outcomes of periampullary cancer in octogenarians. Methods: We retrospectively reviewed medical records of 68 patients over 80 years of age who were diagnosed with periampullary cancer and were eligible for surgery; we analyzed overall survival (OS) and immediate postoperative complications and mortality. Results: There were no significant differences in mean age, disease type, oncologic features, comorbidities, or nutritional status between the patients who had surgery and those who did not. Five patients (20.0%) had major postoperative complications, but there was no immediate postoperative mortality. Patients who had surgery (n=25) had better OS (29.3 months; 95% confidence interval [CI]: 5.6-53.0) than did those who did not (n=43, OS: 7.6 months; 95% CI: 3.2-12.0 months; \(p<0.001\)). Similarly, patients with distal common bile duct cancer who underwent surgery had better OS than those who did not (surgery group: n=13, OS: 29.3 months, 95% CI: 8.9-49.7; non-surgery group: n=15, OS: 5.7 months, 95% CI: 4.2-7.2 months; \(p=0.002\)). Conclusions: Radical surgery for octogenarian patients with periampullary cancer is safe, feasible, and expected to result in better survival outcomes, especially for patients with common bile duct cancer. (Ann Hepatobiliary Pancreat Surg 2018;22:128-135)

Key Words: Periampullary cancer; Octogenarian; Radical surgery; Oncologic outcome; Complication

INTRODUCTION

Increased life expectancy is a global trend; over the past two decades, the mean life expectancy has increased from 64 to 71 years of age, and moreover, the mean life expectancy in high-income countries has increased to nearly 80 years.1 The incidence of cancer increases with age, generating an increased interest in treatments for elderly individuals,2 and therefore, researchers have conducted many studies on surgeries for elderly patients with cancer; clinicians have found that most such surgeries are both safe and feasible, with immediate surgical complications, mortality rates, and long-term outcomes comparable with those in younger patients.2,3,6

Researchers have also reported in multiple studies the efficacy of radical surgery for elderly patients with periampullary adenocarcinoma, and some have reported that selected elderly patients could have similar perioperative outcomes and overall survival (OS) to those in younger adults, although others have shown increased morbidity and mortality in elderly versus younger patients.7-10 In short, the efficacy of surgery for elderly patients with periampullary adenocarcinoma remains a controversial issue in the hepato-pancreato-biliary surgery field.

There are a number of causes for the controversy. Periampullary cancer tends to occur later in life than other malignancies: The median age at diagnosis is about 70 years.2,11,12 Moreover, pancreatoduodenectomy, the radical surgery that is generally performed for such cancers, causes more morbidity and mortality and results in poorer
prognoses than do treatments for other gastrointestinal cancers.\textsuperscript{2,13} Therefore, advanced age has been associated with decreased utilization of surgery to treat periampullary cancer, and the mean age of patients who undergo surgery has remained unchanged over the past decade.\textsuperscript{14}

In recent decades, surgical techniques and postoperative care have significantly improved, and morbidity and mortality after radical surgery have decreased dramatically while mean life expectancy has increased.\textsuperscript{1,13,15} Moreover, radical surgery remains the only potentially curative treatment for periampullary cancer.\textsuperscript{16} Therefore, it is necessary to evaluate radical surgery for periampullary cancer in elderly patients in light of the recent improvements in techniques. We investigated the oncologic outcomes of periampullary cancer in octogenarians, comparing patients who did not receive surgery with those who underwent radical surgery.

\section*{MATERIALS AND METHODS}

We retrospectively reviewed the medical records of 133 patients over 80 years of age who were diagnosed with periampullary cancer from January 2005 to December 2014. We excluded 65 patients who were not able to have radical surgery at the time of diagnosis (e.g., those with distant metastasis) or who were not confirmed by pathology to have periampullary cancer, and we divided the remaining patients into two groups based on whether or not they underwent radical surgery. The surgical criteria for the elderly patients were the same as those for non-elderly patients, and those who were deemed to be operable through preoperative study underwent the surgery. We analyzed immediate postoperative complications and mortality in the patients who had surgery and compared the OS period between the patients who underwent surgery and those who did not.

We used SPSS version 20.0 (IBM Corp., Armonk, NY, USA) for all statistical analyses, and we compared nominal data with $\chi^2$ tests, continuous parametric data with $t$-test, and nonparametric data with Mann-Whitney U tests. We assessed survival parameters by the Kaplan-Meier method and compared them using the log-rank test. The criterion for statistical significance was $p<0.05$.

\begin{table}[h]
\centering
\begin{tabular}{ll}
\hline
\textbf{Variable} & \textbf{N=68} \\
\hline
Age in years (range) & 82 (80-83) \\
Gender (M:F) & 37:31 (1.19:1) \\
BMI & 22.7±0.8 \\
Location of Cancer & \\
CBD & 28 (41.2\%) \\
Pancreas & 16 (23.5\%) \\
AoV & 16 (23.5\%) \\
Duodenum & 8 (11.8\%) \\
Differentiation & \\
Well & 13 (19.1\%) \\
Moderately & 25 (36.8\%) \\
Poorly & 10 (14.7\%) \\
Unknown & 20 (29.4\%) \\
CEA (ng/ml) & 2.63 (1.69-4.07) \\
CA 19-9 (U/ml) & 127 (24-605) \\
Chemotherapy & 12 (17.6\%) \\
Radiotherapy & 8 (11.8\%) \\
Comorbidity & \\
HTN & 52 (76.5\%) \\
DM & 45 (66.2\%) \\
CCS ($\geq3$) & 14 (20.6\%) \\
ASA score ($\geq3$) & 21 (30.9\%) \\
POSSUM score & 12 (17.6\%) \\
Albumin (g/dl) & 3.6±0.1 \\
Lymphocyte (10$^3$/μl) & 1.43±0.2 \\
GNRI & 95.7±2.5 \\
\hline
\end{tabular}
\caption{Basal characteristics of the patients}
\end{table}

BMI, body mass index; CBD, common bile duct; AoV, ampulla of Vater; CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9; HTN, hypertension; DM, diabetes mellitus; CCS, Charlson comorbidity score; ASA, American Society of Anesthesiologists; POSSUM, physiological and operative severity score for the enumeration of mortality and morbidity; GNRI, geriatric nutrition risk index

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig1.png}
\caption{Age distribution of patients with periampullary cancer.}
\end{figure}
**RESULTS**

**Patient distribution**
From January 2005 to December 2014, 2,077 patients were diagnosed with periampullary cancer in our hospital, and among them, 133 (6.4%) were over 80 years of age. More than half of the patients were age 60 to 70 (1,278 patients, 61.6%), and the oldest patient with pancreatic cancer was 96, although that patient was inoperable at the time of diagnosis (Fig. 1).

**Baseline patient characteristics**
The clinicopathologic characteristics of the 68 patients over age 80 who were diagnosed with periampullary cancer are shown in Table 1. The median patient age was 82 years, and the oldest was 90; this patient was in the surgery group. Fifty-two patients (76.5%) had at least one comorbidity. The mean geriatric nutritional risk index (GNRI) was 95.7 (95% confidence interval [CI]: 93.2-98.2).

**Characteristics of the non-surgery group**
Most patients (n=31, 72.1%) refused the surgery due to

---

**Table 2. Basal characteristics of the patients according to treatment**

|                          | Non-surgery (n=43) | Surgery (n=25) | p value |
|--------------------------|--------------------|----------------|---------|
| Age in years (range)     | 83 (80-84)         | 82 (80-83)    | 0.101   |
| Gender (M:F)             | 23:20 (1.15:1)     | 14:11 (1.27:1)| 0.841   |
| BMI (range)              | 22.5 (16.5-32.1)   | 23.1 (16.8-29.6)| 0.686  |
| Location of Cancer       |                    |                |         |
| CBD                      | 15 (34.9%)         | 13 (52.0%)     |         |
| Pancreas                 | 12 (27.9%)         | 4 (16.0%)      |         |
| AoV                      | 12 (27.9%)         | 4 (16.0%)      |         |
| Duodenum                 | 4 (9.3%)           | 4 (16.0%)      |         |
| Differentiation          |                    |                |         |
| Well                     | 9 (20.9%)          | 4 (16.0%)      |         |
| Moderately               | 14 (32.6%)         | 11 (44.0%)     |         |
| Poorly                   | 6 (13.9%)          | 4 (16.0%)      |         |
| Unknown                  | 14 (32.6%)         | 6 (24.0%)      |         |
| CEA (>5 ng/ml)           | 8 (18.6%)          | 2 (8.0%)       | 0.228   |
| CA 19-9 (>37 U/ml)       | 34 (79.1%)         | 16 (64.0%)     | 0.170   |
| Chemotherapy             | 5 (11.6%)          | 2 (8.0%)       | 0.088   |
| Radiotherapy             | 6 (14.0%)          | 2 (8.0%)       | 0.463   |
| Comorbidity              | 34 (79.0%)         | 18 (72.0%)     | 0.508   |
| HTN                      | 29 (67.4%)         | 16 (64.0%)     | 0.772   |
| DM                       | 9 (20.9%)          | 5 (20.0%)      | 0.927   |
| CCS (≥3)                 | 15 (34.9%)         | 6 (24.0%)      | 0.349   |
| ASA score (≥3)           | 10 (23.3%)         | 2 (8.0%)       | 0.112   |
| POSSUM score (≥24)       | 16 (37.2%)         | 6 (24.0%)      | 0.262   |
| Albumin (<3.0 g/dl)      | 4 (9.3%)           | 1 (4.0%)       | 0.419   |
| Lymphocyte (<2000/μl)    | 35 (81.4%)         | 21 (84.0%)     | 0.786   |
| GNRI (≥3)                | 18 (43.9%)         | 7 (28.0%)      | 0.196   |

BMI, body mass index; CBD, common bile duct; AoV, ampulla of Vater; CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9; HTN, hypertension; DM, diabetes mellitus; CCS, Charlson comorbidity score; ASA, American Society of Anesthesiologists; POSSUM, physiological and operative severity score for the enumeration of mortality and morbidity; GNRI, geriatric nutrition risk index
their old age, and the other patients’ data did not exist in the medical records (n=12, 27.9%). Among the patients who refused the surgery, 14 decided independently, and family members made the decision for the other 17 (Fig. 2).

Clinicopathologic characteristics according to radical surgery

We divided the 68 patients into two groups based on whether or not they underwent radical surgery. Forty-three patients did not undergo surgery, and the other 25 did, and there was no significant difference in median age between the two groups (non-surgery: 83 years, surgery: 82; years p=0.101). There were also no significant differences in tumor characteristics (tumor location and differentiation), comorbidity status (Charlson comorbidity score [CCS] and American Society of Anesthesiologist [ASA] classification), or nutritional status including GNRI (Table 2).

Characteristics of the surgery group

Most of the patients who underwent radical surgery were within TNM stage II; only two were beyond stage II, and both of them were confirmed to have duodenal cancer (Fig. 3A). Twenty-two patients (88.0%) had immediate postoperative complications; however, most of the complications were minor, and only five (20.0%) had major complications that exceeded Clavien-Dindo grade III17 (Fig. 3B). Between the elderly and non-elderly (n=678) groups, there were no significant differences in complication rates (elderly: 11.5%, non-elderly: 20.0%; p=0.202).

Oncologic outcomes of elderly patients

The mean OS was 37.7 months (range: 26.1-49.3 months), and there was a significant difference in OS between the two groups (non-surgery vs. surgery: 7.6 months vs. 29.3 months; p<0.001). Fifty-six patients (82.4%) expired, and all of the causes of death were cancer related (Fig. 4A).

Subgroup analysis showed that patients with common bile duct (CBD) cancer who underwent surgery (n=13) had better OS than did those with CBD cancer who did not (n=15): 5.7 months vs. 29.3 months (p=0.002). However, there were no significant differences between the two groups in clinicopathologic parameters except for CCS (non-surgery vs. surgery: 0.0% vs. 30.8%, p=0.035; Table 3). Comparisons among other subgroups either showed no significant differences between patients in the surgery and non-surgery groups or could not provide statistical results because of the small sample sizes of the subgroups (Fig. 4B-E).

DISCUSSION

As the human body ages, there is a progressive decline in physiologic functioning that affects all organ systems and places elderly individuals at increased risk of disease. Although the gastrointestinal system is less affected than other systems, aging can lead to a decline in metabolism,18 and moreover, aging is a risk factor for most cancers. There is abundant literature that explains the relationship between aging and cancer. Carcinogenesis often occurs over a long period of time and is promoted by the
increased susceptibility of older tissues to environmental carcinogens and by changes in the body environment that occur with aging, such as chronic inflammation and increased resistance to insulin.\textsuperscript{19,20} Therefore, elderly patients should not be considered to be the same as younger patients.

There are few evidence-based guidelines for elderly patients with cancer, and oncologists are often faced with special challenges when managing these patients;\textsuperscript{21} most oncologists agree, however, that estimating life expectancy is of primary importance. In addition, clinicians should determine whether the assumed treatment benefits

Fig. 4. Overall survival rates of elderly patients with periampullary cancer; (A) Total, (B) common bile duct (CBD), (C) Pancreas, (D) Ampulla of Vater (AoV) and (E) Duodenum.
Table 3. Basal characteristics of elderly patients with distal CBD cancer

|                          | Non-surgery (n=15) | Surgery (n=13) | p value |
|--------------------------|--------------------|----------------|---------|
| Age in years (range)     | 81 (80-88)         | 81 (80-90)     | 0.446   |
| Gender (M:F)             | 6:9 (0.67:1)       | 7:6 (1.17:1)   | 0.464   |
| BMI (range)              | 22.7 (20.5-24.9)   | 23.3 (21.4-25.2)| 0.686   |
| Differentiation          |                    |                | 0.469   |
| Well                     | 6 (40.0%)          | 3 (23.1%)      |         |
| Moderately               | 7 (46.6%)          | 5 (38.5%)      |         |
| Poorly                   | 1 (6.7%)           | 2 (15.3%)      |         |
| Unknown                  | 1 (6.7%)           | 3 (23.1%)      |         |
| CEA (>5 ng/ml)           | 1 (6.7%)           | 2 (15.3%)      | 0.457   |
| CA 19-9 (>37 U/ml)       | 13 (86.7%)         | 6 (31.6%)      | 0.051   |
| Chemotherapy             | 1 (6.7%)           | 1 (7.7%)       | 0.916   |
| Radiotherapy             | 2 (13.3%)          | 2 (15.4%)      | 0.463   |
| Comorbidity              | 11 (73.3%)         | 10 (76.9%)     | 0.827   |
| HTN                      | 11 (73.3%)         | 8 (61.5%)      | 0.505   |
| DM                       | 1 (6.7%)           | 3 (23.1%)      | 0.216   |
| CCS (≥3)                 | 0 (0.0%)           | 4 (30.8%)      | 0.035   |
| ASA score (≥3)           | 2 (13.3%)          | 2 (15.4%)      | 0.877   |
| POSSUM score (≥24)       | 4 (26.7%)          | 4 (30.8%)      | 0.811   |
| Albumin (<3.0 g/dl)      | 2 (13.3%)          | 0 (0.0%)       | 0.172   |
| Lymphocyte (<2000/µl)    | 13 (86.7%)         | 11 (84.6%)     | 0.877   |
| GNRI (≥3)                | 9 (64.3%)          | 3 (23.1%)      | 0.054   |

BMI, body mass index; CBD, common bile duct; AoV, ampulla of Vater; CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9; HTN, hypertension; DM, diabetes mellitus; CCS, Charlson comorbidity score; ASA, American Society of Anesthesiologists; POSSUM, physiological and operative severity score for the enumeration of mortality and morbidity; GNRI, geriatric nutrition risk index

will likely occur within the patient’s remaining life span. Because life expectancy is heterogeneous among elderly patients, it is not a simple issue to determine the likely efficacy of a given treatment; comorbidities, disability, and geriatric syndromes have a substantial impact on life expectancy.22

Because of the complexities of cancer management in elderly patients, comprehensive geriatric assessment (CGA) is in the interest of oncologists. CGA is a global, multidisciplinary approach to elderly patients that covers functional status, cognitive capacities, emotional status, comorbidities, nutritional status, polypharmacy, and social and environmental circumstances.23 Recently, several studies showed that CGA could help to adapt cancer management to each patient’s fitness or frailty.24,25 Although CGA can predict morbidity and mortality in elderly patients with cancer, its implications are more complex for surgical oncologists;23 surgery is one of the most invasive treatments and can cause more complications than other treatment modalities.26 Above all, radical surgery for peri-ampullary cancer is generally associated with high morbidity and mortality rates and requires many days of hospitalization, leading to fears among surgical oncologists about treatment-related adverse effects.13

To avoid unwanted postoperative morbidity and mortality, researchers have conducted many studies on predictive preoperative indexes for elderly patients.26-29 and comorbidities are one of the risk factors. Eighty-three percent of elderly patients have at least one comorbidity, although two thirds have acceptable preoperative functional and mental status.26,28 In addition, the ASA grade and the GNRI can predict postoperative complications;27,29,30 in our study, there was no significant difference in ASA grade or GNRI between the patients who underwent radical surgery and those who did not. The CCS and the Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (POSSUM) are additional predictive factors, although their predictive value has not been validated in elderly patients.31,32 in our study, there was no significant difference in these scores between the elderly and non-elderly patients.

Many studies that evaluated safety, feasibility, and out-
comes in elderly patients with periampullary cancer have been conducted, but most of these studies defined elderly patients as septuagenarians; there are only a few reports on octogenarians, and these showed major postoperative complication rates from 32.2 to 50.0%. In our study, the major complication rate was 20.0%, and the lower rate in our study was likely because we included recent operations; our rate was similar to the rate in another recent report of complication rates. In addition, with the exception of the patients with duodenal cancer, the TNM stages of periampullary adenocarcinoma in our study were below stage III. Our results suggest that the patients in our study who underwent surgery were surgically and oncologically appropriate for the treatment they received.

Although we could not directly know the TNM stages of the patients in the non-surgery group, there were no significant differences in tumor markers or tumor differentiation between the surgery and non-surgery groups; we therefore inferred indirectly that there were likely not significant differences in TNM stages between the two groups. In addition, we performed a subgroup analysis to compensate for the heterogeneity of the study group, and that analysis showed that patients with distal CBD cancer who underwent surgery had better OS than did those who did not, although there were no differences in baseline characteristics between the two groups except for CCS, which was higher in the surgery subgroup than in the non-surgery group.

The main focus of the previous articles on octogenarians was not oncologic outcomes but rather surgical safety and feasibility, whereas we evaluated not only surgical safety and feasibility but also surgical oncologic outcomes; moreover, the control group in our study consisted of elderly patients who did not undergo surgery. Most of the previous studies compared elderly patients with younger patients to evaluate the oncologic outcomes; moreover, the control group in our study consisted of elderly patients who did not undergo surgery.

Our study has major limitations due to its retrospective design and its heterogeneous study group, which was affected by various diseases; although the subgroup analysis accounted for the heterogeneity of the study group, we were only able to statistically analyze the subgroup with distal CBD cancer because of the small sample size. Moreover, in elderly patients, quality of life is as important as life expectancy, and because of the retrospective study design, we could not include parameters that estimated the elderly patients’ quality of life.

Nevertheless, our study provides significant results concerning radical surgery for elderly patients with periampullary cancer. Specifically, radical surgery for certain octogenarian patients with periampullary cancer is safe and feasible and can be expected to result in better survival outcomes, especially for patients with CBD cancer. Further study is warranted to develop a more sophisticated system for selecting elderly patients to obtain better outcomes.

REFERENCES

1. Mathers CD, Stevens GA, Boerma T, White RA, Tobias MI. Causes of international increases in older age life expectancy. Lancet 2015;385:540-548.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
3. Seishima R, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Matsui S, et al. Is laparoscopic colorectal surgery beneficial for elderly patients? A systematic review and meta-analysis. J Gastrointest Surg 2015;19:756-765.
4. Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. Surg Endosc 2015;29:2321-2330.
5. Kishida N, Hibi T, Itano O, Okabayashi K, Shinoda M, Kitago M, et al. Validation of hepatectomy for elderly patients with hepatocellular carcinoma. Ann Surg Oncol 2015;22:3094-3101.
6. Lee CR, Lim JH, Kim SH, Ahn SH, Park YN, Choi GH, et al. A comparative analysis of hepatocellular carcinoma after hepatic resection in young versus elderly patients. J Gastrointest Surg 2012;16:1736-1743.
7. Haigh PI, Bilimoria KY, DiFronzo LA. Early postoperative outcomes after pancreaticoduodenectomy in the elderly. Arch Surg 2011;146:715-723.
8. Lee DY, Schwartz JA, Wexelman B, Kirchoff D, Yang KC, Attiyeh F. Outcomes of pancreaticoduodenectomy for pancreatic malignancy in octogenarians: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg 2014;207:540-548.
9. Turrini O, Paye F, Bachellier P, Sauvanet A, Sa Cunha A, Le Trait YP, et al. Pancreatectomy for adenocarcinoma in elderly patients: postoperative outcomes and long term results: a study of the French Surgical Association. Eur J Surg Oncol 2013;39:171-178.
10. de la Fuente SG, Bennett KM, Pappas TN, Scarborough JE. Pre-and intraoperative variables affecting early outcomes in elderly patients undergoing pancreaticoduodenectomy. HPB (Oxford) 2011;13:887-892.
11. Buchbinder T, Frisstrup C, Mortensen MB. The incidence and prognosis of true duodenal carcinomas. Surg Oncol 2015;24:110-116.
12. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. The incidence and prognosis of true duodenal carcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007;99:895-897.
13. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-15.
14. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173-180.
15. Fernández-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995;130:295-299.
16. Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2014;12:1083-1093.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
18. Homeier D. Aging: physiology, disease, and abuse. Clin Geriatr Med 2014;30:671-686.
19. Hoffe S, Balducci L. Cancer and age: general considerations. Clin Geriatr Med 2012;28:1-18.
20. Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005;5:655-662.
21. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716-724.
22. Kilari D, Mohile SG. Management of cancer in the older adult. Clin Geriatr Med 2012;28:33-49.
23. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-1831.
24. Corre R, Greillier L, Le Caër H, Audigier-Vallette C, Baize N, Bénard H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGA-GFPC-GECP 08-02 study. J Clin Oncol 2016;34:1476-1483.
25. Girre V, Falcou MC, Gisselbrecht M, Gridel G, Mosseri V, Boulec C, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 2008;63:724-730.
26. Zbar AP, Gravitza A, Audisio RA. Principles of surgical oncology in the elderly. Clin Geriatr Med 2012;28:51-71.
27. Kaza MA, Terzioglu İ, Genç V, Erkek AB, Ozban M, Sonyürek P, et al. Preoperative nutritional risk assessment in predicting postoperative outcome in patients undergoing major surgery. World J Surg 2006;30:378-390.
28. Casadei R, Zanini N, Morselli-Labate AM, Calculi L, Pezzilli R, Potì O, et al. Prognostic factors in peripancreatic and pancreatic tumor resection in elderly patients. World J Surg 2006;30:1992-2001.
29. Abd-Al-Gawad WM, Abou-Hashem RM, El Maraghy MO, Amin GE. The validity of Geriatric Nutrition Risk Index: simple tool for prediction of nutritional-related complication of hospitalized elderly patients. Comparison with Mini Nutritional Assessment. Clin Nutr 2014;33:1108-1116.
30. PACE participants, Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008;65:156-163.
31. Prytherch DR, Whiteley MS, Higgins B, Weaver PC, Prout WG, Powell SJ. POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity. Br J Surg 1998;85:1217-1220.
32. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-682.
33. Barbos AS, Turley RS, Ceppa EP, Reddy SK, Blazer DG 3rd, Clary BM, et al. Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J Am Geriatr Soc 2012;60:344-350.
34. Oliveira-Cunha M, Malde DJ, Aldouri A, Morris-Stiff G, Menon KV, Smith AM. Results of pancreatic surgery in the elderly: is age a barrier? HPB (Oxford) 2013;15:24-30.
35. de Franco V, Frampas E, Wong M, Meurette G, Charvin M, Leborgne J, et al. Safety and feasibility of pancreaticoduodenectomy in the elderly: a matched study. Pancreas 2011;40:924-929.
36. Staufer JA, Grewal MS, Martin JK, Nguyen JH, Asbun HJ. Pancreas surgery is safe for octogenarians. J Am Geriatr Soc 2011;59:184-186.
37. Khan S, Scabas G, Lombardo KR, Sarr MG, Nagorney D, Kendrick ML, et al. Pancreaticoduodenectomy for ductal adenocarcinoma in the very elderly; is it safe and justified? J Gastrointest Surg 2010;14:1826-1831.
38. Adebayo P, Obirieze A, Onwugbufor M, Cole M, Cornwell EE 3rd, Frederick WA. The impact of complications after pancreaticoduodenectomy in elderly patients: a review of the Nationwide Inpatient Sample database. Am Surg 2014;80:1175-1178.
39. Melis M, Marcon F, Masì A, Pinna A, Sarpe U, Miller G, et al. The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. HPB (Oxford) 2012;14:583-588.